论文部分内容阅读
目的:评价细胞因子诱导的杀伤细胞(CIK)联合化疗治疗晚期卵巢癌的疗效、不良反应及对患者生活质量的影响。方法:将68例晚期卵巢癌患者随机分为单纯化疗组37例,给予TC(紫杉醇+卡铂)方案化疗,每3周重复;联合治疗组31例,于化疗的基础上再予以CIK细胞治疗,至少2周期后评价疗效,观察疗效、免疫功能、不良反应及生活质量。结果:治疗2个疗程后,联合治疗组患者外周血CD3+、CD4+/CD8+水平明显高于单纯化疗组,差异有统计学意义(P<0.05)。两组患者疾病控制率分别为75.6%和87.1%,差异有统计学意义(P<0.05),联合治疗组患者较单纯化疗患者PFS延长2.5个月。联合治疗组患者生活质量改善情况优于单纯化疗组,两组卡氏评分下降百分比比较差异有统计学意义(P<0.05)。联合治疗组患者血红蛋白、白细胞、血小板的损害均低于单纯化疗组,差异有统计学意义(P<0.05)。结论:CIK细胞联合化疗治疗晚期卵巢癌可提高疗效及疾病控制率,其综合治疗效果明显优于单纯化疗组。
OBJECTIVE: To evaluate the efficacy, adverse reactions and quality of life of patients with advanced ovarian cancer treated with cytokine-induced killer (CIK) combined with chemotherapy. Methods: A total of 68 patients with advanced ovarian cancer were randomly divided into chemotherapy group (n = 37) and chemotherapy regimen (paclitaxel plus carboplatin). The chemotherapy regimen was repeated every 3 weeks. In combination therapy group, 31 patients were treated with CIK cells , At least 2 cycles after the evaluation of efficacy, efficacy, immune function, adverse reactions and quality of life. Results: After 2 courses of treatment, the levels of CD3 + and CD4 + / CD8 + in the peripheral blood of the combined treatment group were significantly higher than those of the chemotherapy alone group (P <0.05). The disease control rates of the two groups were 75.6% and 87.1%, respectively, with significant difference (P <0.05). The PFS in combination therapy group was 2.5 months longer than that of chemotherapy alone group. The improvement of quality of life in the combined treatment group was better than that of the chemotherapy alone group, and the difference between the two groups was statistically significant (P <0.05). The combined treatment group patients with hemoglobin, white blood cells, platelet damage were lower than the chemotherapy alone group, the difference was statistically significant (P <0.05). Conclusion: CIK cells combined with chemotherapy for advanced ovarian cancer can improve the efficacy and disease control rate, the comprehensive treatment effect was significantly better than the simple chemotherapy group.